AD
ADAG.US Adagene Inc
- Market cap
- USD 134M
- P/E
- -
- P/B
- 1.60x
- ROE
- -38.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ADAG.US undervalued?
Graham numberThe Graham number of Adagene Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Adagene Inc fundamental analysis
No fundamental analysis for Adagene Inc yet.
Adagene Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Adagene Inc
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials …
Full company profileAdagene Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Adagene Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 1.51M | 480K | 480K | 10.2M | 9.29M | 18.1M | 103K | 7.67M | 18.6M |
| Gross Profit | 1.51M | 480K | 480K | 10.2M | 9.29M | 18.1M | -823K | 7.67M | 17.6M |
| Operating Income | -17.3M | -19.2M | -19.2M | -72.4M | -83.9M | -23.7M | -36.0M | -21.4M | -44.8M |
| EBITDA | -14.3M | -15.5M | -41.3M | -70.0M | -77.4M | -15.0M | -31.7M | -16.9M | -43.7M |
| Net Income | -14.7M | -17.3M | -16.4M | -73.2M | -80.0M | -18.9M | -33.4M | -17.6M | -41.1M |
| EPS | -1.52 | -0.49 | -0.59 | -2.29 | -2.31 | -0.54 | -0.93 | -0.47 | -0.91 |
| Balance Sheet | |||||||||
| Total Assets | 54.4M | 106M | 84.3M | 190M | 152M | 116M | 89.3M | 78.3M | 134M |
| Total Liabilities | 95.4M | 163M | 174M | 33.0M | 69.3M | 45.2M | 38.7M | 42.9M | 27.6M |
| Shareholders' Equity | -41.0M | -57.0M | -89.4M | 157M | 83.1M | 70.6M | 50.5M | 35.3M | 106M |
| Cash & Short-term Investments | 49.1M | 101M | 75.2M | 174M | 144M | 110M | 85.2M | 74.5M | 128M |
| Total Debt | 2.33M | 2.56M | 7.98M | 7.49M | 28.0M | 22.3M | 18.5M | 6.26M | 6.09M |
| Cash Flow | |||||||||
| Operating Cash Flow | -14.3M | -18.2M | -28.5M | -43.4M | -48.6M | -28.5M | -29.7M | -15.7M | -38.6M |
| Capital Expenditure | 515K | 152K | 935K | 2.51M | 691K | 85.0K | 33.6K | 17.1K | 342K |
| Free Cash Flow | -14.8M | -18.3M | -29.5M | -45.9M | -49.3M | -28.5M | -29.7M | -15.7M | -38.9M |
| Ratios | |||||||||
| ROE | - | - | - | -46.7% | -96.2% | -26.9% | -66.2% | -49.8% | -38.8% |
| ROA | -27.0% | -16.3% | -19.5% | -38.6% | -52.5% | -16.4% | -37.4% | -22.5% | -30.8% |
| Net Profit Margin | -974.0% | -3,602.9% | -3,424.1% | -719.2% | -860.6% | -104.6% | -32,386.4% | -229.6% | -220.7% |
| Debt to Equity | - | - | - | 0.05x | 0.34x | 0.32x | 0.37x | 0.18x | 0.06x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Adagene Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 323K | 0.01 | - |
| 2021 | USD 4.61M | 0.14 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Adagene Inc
- Insiders 11.40%
- Institutions 32.74%
- Public & others 55.86%
- Shares outstanding 67.1M
- Free float 44.8M
Top funds holding ADAG.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fullgoal Glb Healt Life Alloc(QDII)USD | 150K | 0.22% | +42.86% | Jun 2026 |
| Invesco Golden Dragon China ETF | 52.2K | 0.08% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 38.4K | 0.06% | 0.00% | Aug 2026 |
| State Street® SPDR® S&P® EM Sm Cp ETF | 27.4K | 0.04% | 0.00% | Oct 2026 |
Top institutions holding ADAG.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Jupiter Topco LLC | 6.67M | 9.93% | 0.00% | Jun 2026 |
| Siren, L.L.C. | 2.67M | 3.97% | 0.00% | Jun 2026 |
| Deerfield Management Co | 2.67M | 3.97% | 0.00% | Jun 2026 |
| Ameriprise Financial Inc | 1.72M | 2.56% | +182.40% | Jun 2026 |
| HSG Holding Ltd | 1.34M | 2.00% | 0.00% | Jun 2026 |
| Squadron Capital Management LLC | 1.25M | 1.86% | 0.00% | Jun 2026 |
| Dauntless Investment Group, LLC | 537K | 0.80% | +1,444.87% | Jun 2026 |
| Citadel Advisors Llc | 507K | 0.76% | 0.00% | Jun 2026 |
| Exome Asset Management LLC | 488K | 0.73% | -33.73% | Jun 2026 |
| Birchview Capital, LP | 240K | 0.36% | 0.00% | Jun 2026 |
| Moneta Group Investment Advisors Inc | 200K | 0.30% | 0.00% | Jun 2026 |
| Pathstone Holdings LLC | 200K | 0.30% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 147K | 0.22% | +324.23% | Jun 2026 |
| UBS Group AG | 124K | 0.18% | +3,000.03% | Jun 2026 |
| The Goldman Sachs Group Inc | 106K | 0.16% | 0.00% | Jun 2026 |
| Quadrature Capital Limited | 80.5K | 0.12% | +592.84% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 69.1K | 0.10% | 0.00% | Jun 2026 |
| Amvescap Plc. | 42.9K | 0.06% | -8.87% | Jun 2026 |
| SmartHarvest Portfolios, LLC | 41.7K | 0.06% | +3.43% | Jun 2026 |
| Kamunting Street Cap Management, L.p. | 38.1K | 0.06% | 0.00% | Jun 2026 |
Adagene Inc company profile
- Company name
- Adagene Inc
- Ticker
- ADAG.US
- Exchange
- USA Stocks
- Listed since
- Feb 9, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 128
- Fiscal year end
- December
- Address
- Building C14, Suzhou, China, 215123
- Phone
- 86 512 8777 3632
- Website
- adagene.com
About Adagene Inc
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
Adagene Inc management
10- Dr. Peter P. Luo Ph.D.Co- Founder, Chairman, CEO and President of R&D · born 1966
- Mr. Man Kin Tam M.B.A.CFO & Director · born 1977
- Ms. Ling ZhouExecutive Director & Head of Human Resources
- Dr. Qinghai Zhao Ph.D.Chief Manufacturing Officer · born 1961
- Mr. Mickael Chane-DuChief Strategy Officer
- Ms. Yan Li M.B.A.Senior Vice President of Bioinformatics & Information Technology · born 1975
- Ms. Xiaohong SheSenior VP & Head of Clinical Operations · born 1967
- Dr. Guizhong Liu Ph.D.Senior Vice President of Early Drug Discovery · born 1971
- Mr. Alexander GoergenVP & Head of Business Development · born 1987
- Dr. Jiping Zha M.D., Ph.D.Executive Vice President of Clinical Development